Literature DB >> 2501185

Assay discrepancies with highly purified factor VIII concentrates.

N J Dawson1, G Kemball-Cook, T W Barrowcliffe.   

Abstract

We have assayed two different monoclonal-antibody-purified concentrates (A and B) and one conventional concentrate (C), against the 3rd International Standard for factor VIII concentrate, using one-stage, two-stage and chromogenic methods. One-stage assays performed with immunodepleted plasmas gave lower potencies than with haemophilic plasma for all concentrates, though the discrepancies were most marked for the two highly purified products. The absence of von Willebrand factor in one of the immunodepleted plasmas appeared to contribute towards the low potencies observed. In addition, potencies of product A were 50% higher by one-stage assays (haemophilic plasma) than by two-stage or chromogenic methods. These results indicate the need for careful evaluation of assay methodologies for assessment of factor VIII:C activity in highly purified concentrates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501185     DOI: 10.1159/000215905

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  4 in total

1.  Discrepant In Vivo Recovery of Factor VIII:C Following Infusion of Two Different Monoclonal Factor VIII Preparations.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

Review 2.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies.

Authors:  S Björkman; M Carlsson; E Berntorp; P Stenberg
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

4.  Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.

Authors:  J M Sommer; N Moore; B McGuffie-Valentine; S Bardan; Y Buyue; G D Kamphaus; B A Konkle; G F Pierce
Journal:  Haemophilia       Date:  2013-11-22       Impact factor: 4.287

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.